Department of Endocrinology and Metabolism, The First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, P. R. China Jiangxi Clinical Research Center for Endocrine and ...
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a relatively new class of oral diabetes drugs. Also known as gliptins, they are usually prescribed for people with type 2 diabetes who have not responded ...
DPP-4 exists as both a membrane-bound and soluble form. DPP-4 has historically been associated with its capacity to metabolize incretin hormones. Recent studies have identified additional functions of ...
Among patients with type 2 diabetes, no differences were found with biguanides vs DPP-4 inhibitors in major cardiac or cerebrovascular events, diabetic complications, or death. Biguanides vs ...
CXCR3 is a chemokine receptor with three ligands: CXCL9, CXCL10, and CXCL11. Cancer patients with low CXCL9 or CXCL10 levels exhibit a reduced response to the main immune checkpoint inhibitor PD-1, as ...
Compared with DPP-4 inhibitor therapy, sustained GLP-1 receptor agonist (GLP-1 RA) therapy was associated with greater short‑ and long‑term improvements in A1c levels and a modest reduction in the ...
Type 2 diabetes already affects 230 million people and is rising at epidemic levels with a worldwide prevalence of 350 million forecast for 2025. The global population is getting progressively older ...
5 Catholic Kwandong University College of Medicine Department of Medical Science, Gangneung-si, The Republic of Korea Background Dipeptidyl peptidase-4 inhibitors (DPP-4is) have been reported to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results